[{"id":"f2099dc8-cbfe-4cc7-a261-30a50590ba1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06547112","created_at":"2025-02-25T12:39:11.165Z","updated_at":"2025-02-25T12:39:11.165Z","phase":"Phase 1","brief_title":"A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization","source_id_and_acronym":"NCT06547112","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aphexda (motixafortide)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"b8897926-0522-4fee-9673-a3eb75b62670","acronym":"","url":"https://clinicaltrials.gov/study/NCT03173937","created_at":"2021-01-18T15:38:57.471Z","updated_at":"2025-02-25T13:39:29.284Z","phase":"Phase 1/2","brief_title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","source_id_and_acronym":"NCT03173937","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD34 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Omisirge (omidubicel)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 04/28/2025","primary_completion_date":" 04/28/2025","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-21"},{"id":"13a8ea63-40e9-404c-b670-688e9b2c8b54","acronym":"LuDO-N","url":"https://clinicaltrials.gov/study/NCT04903899","created_at":"2021-05-27T13:53:06.417Z","updated_at":"2025-02-25T15:26:53.866Z","phase":"Phase 2","brief_title":"177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk Neuroblastoma","source_id_and_acronym":"NCT04903899 - LuDO-N","lead_sponsor":"Jakob Stenman","biomarkers":" SSTR • CD34 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression","tags":["SSTR • CD34 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 05/20/2031","study_completion_date":" 05/20/2031","last_update_posted":"2025-02-11"},{"id":"0f0a2dc6-cfa3-4fe4-b319-c5a4a3207380","acronym":"FRE","url":"https://clinicaltrials.gov/study/NCT05824689","created_at":"2023-04-21T15:04:43.422Z","updated_at":"2025-02-25T15:36:10.840Z","phase":"","brief_title":"Fluoroquinolone Resistance Prevalence Study","source_id_and_acronym":"NCT05824689 - FRE","lead_sponsor":"Hackensack Meridian Health","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 12/17/2024","primary_completion_date":" 12/17/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-10"},{"id":"45b2704f-6ced-4f5c-956f-04b2574840c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04543903","created_at":"2024-01-03T15:17:28.791Z","updated_at":"2025-02-25T16:32:13.553Z","phase":"","brief_title":"Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer","source_id_and_acronym":"NCT04543903","lead_sponsor":"Alpha Tau Medical LTD.","biomarkers":" BRCA1 • CD34 • XRCC2","pipe":"","alterations":" ","tags":["BRCA1 • CD34 • XRCC2"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/16/2022","start_date":" 05/16/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-07"},{"id":"ba0b6173-d6ba-4d9f-b7a6-14e36795d0f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02337985","created_at":"2021-01-18T11:06:20.660Z","updated_at":"2025-02-25T16:36:30.633Z","phase":"Phase 1","brief_title":"Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02337985","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • etoposide oral • vincristine • prednisone • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 11/20/2015","start_date":" 11/20/2015","primary_txt":" Primary completion: 10/02/2025","primary_completion_date":" 10/02/2025","study_txt":" Completion: 10/02/2025","study_completion_date":" 10/02/2025","last_update_posted":"2025-02-06"},{"id":"33da474f-b112-4a34-ad2b-bf3aa8c54e06","acronym":"AALL1231","url":"https://clinicaltrials.gov/study/NCT02112916","created_at":"2021-01-18T09:46:35.591Z","updated_at":"2025-02-25T16:51:23.270Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT02112916 - AALL1231","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 847","initiation":"Initiation: 10/04/2014","start_date":" 10/04/2014","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-04"},{"id":"641e6271-0e87-4441-87f5-e22bb1c67e28","acronym":"IFN\u0026SMP","url":"https://clinicaltrials.gov/study/NCT05850273","created_at":"2023-05-09T14:04:26.422Z","updated_at":"2025-02-25T16:54:57.682Z","phase":"","brief_title":"Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms","source_id_and_acronym":"NCT05850273 - IFN\u0026SMP","lead_sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","biomarkers":" CD38 • CD34 • THY1","pipe":"","alterations":" ","tags":["CD38 • CD34 • THY1"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 03/16/2028","primary_completion_date":" 03/16/2028","study_txt":" Completion: 03/16/2033","study_completion_date":" 03/16/2033","last_update_posted":"2025-02-04"},{"id":"a5f14953-ab61-4581-b513-a86ad8a1e2b8","acronym":"AALL0434","url":"https://clinicaltrials.gov/study/NCT00408005","created_at":"2021-01-17T17:29:32.376Z","updated_at":"2025-02-25T16:50:52.092Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT00408005 - AALL0434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO","pipe":" | ","alterations":" CD22 expression","tags":["CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1895","initiation":"Initiation: 01/22/2007","start_date":" 01/22/2007","primary_txt":" Primary completion: 09/30/2017","primary_completion_date":" 09/30/2017","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-04"},{"id":"b1018fa9-fe4d-453b-84e2-5cea26a0b9e5","acronym":"NCI-2016-01300","url":"https://clinicaltrials.gov/study/NCT02879695","created_at":"2021-01-18T14:08:12.480Z","updated_at":"2025-02-25T16:51:44.591Z","phase":"Phase 1","brief_title":"Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia","source_id_and_acronym":"NCT02879695 - NCI-2016-01300","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19 • CD34 • MME","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD34 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Blincyto (blinatumomab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/25/2017","start_date":" 10/25/2017","primary_txt":" Primary completion: 05/22/2023","primary_completion_date":" 05/22/2023","study_txt":" Completion: 07/18/2025","study_completion_date":" 07/18/2025","last_update_posted":"2025-02-04"},{"id":"8ec351f2-1bd5-4f00-9a41-65c5a39f754f","acronym":"HTLP-ONCO","url":"https://clinicaltrials.gov/study/NCT04707300","created_at":"2021-01-19T20:51:47.092Z","updated_at":"2025-02-25T17:00:53.937Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients with Hematologic Malignancies (HTLP-ONCO)","source_id_and_acronym":"NCT04707300 - HTLP-ONCO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" HLA-DRB1 • CD34 • CD4 • CD7","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["HLA-DRB1 • CD34 • CD4 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMART 102"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/16/2022","start_date":" 02/16/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-03"},{"id":"7ad02231-e51d-4e77-bde9-f01924b1ddec","acronym":"PELICAN","url":"https://clinicaltrials.gov/study/NCT06232564","created_at":"2024-01-30T19:21:28.994Z","updated_at":"2025-02-25T17:32:47.858Z","phase":"Phase 2","brief_title":"A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs","source_id_and_acronym":"NCT06232564 - PELICAN","lead_sponsor":"Imperial College London","biomarkers":" PD-1 • VEGFA • CD34 • FOXP3","pipe":"","alterations":" ","tags":["PD-1 • VEGFA • CD34 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/08/2024","start_date":" 07/08/2024","primary_txt":" Primary completion: 03/02/2028","primary_completion_date":" 03/02/2028","study_txt":" Completion: 08/02/2028","study_completion_date":" 08/02/2028","last_update_posted":"2025-01-30"},{"id":"bb6fe11c-92d7-43aa-a535-cfa2d75b128c","acronym":"CNS-PHLAT","url":"https://clinicaltrials.gov/study/NCT06687772","created_at":"2025-02-25T19:05:14.187Z","updated_at":"2025-02-25T19:05:14.187Z","phase":"Phase 2","brief_title":"CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant","source_id_and_acronym":"NCT06687772 - CNS-PHLAT","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carmustine • melphalan • thiotepa"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/16/2025","start_date":" 01/16/2025","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 07/31/2029","study_completion_date":" 07/31/2029","last_update_posted":"2025-01-22"},{"id":"1acb7aaf-3833-4bea-94c7-39bf5affa991","acronym":"","url":"https://clinicaltrials.gov/study/NCT06727383","created_at":"2025-02-26T10:10:12.911Z","updated_at":"2025-02-26T10:10:12.911Z","phase":"","brief_title":"CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors","source_id_and_acronym":"NCT06727383","lead_sponsor":"European Institute of Oncology","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/21/2022","start_date":" 12/21/2022","primary_txt":" Primary completion: 12/21/2025","primary_completion_date":" 12/21/2025","study_txt":" Completion: 12/21/2025","study_completion_date":" 12/21/2025","last_update_posted":"2024-12-10"},{"id":"f856673f-5509-490b-a1a0-017a3519e174","acronym":"EPBSCH","url":"https://clinicaltrials.gov/study/NCT05961410","created_at":"2023-07-27T18:09:07.280Z","updated_at":"2025-02-25T15:54:51.323Z","phase":"Phase 2","brief_title":"Eltrombopag for Peripheral Blood Stem Cell Harvest","source_id_and_acronym":"NCT05961410 - EPBSCH","lead_sponsor":"National Taiwan University Hospital","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promacta (eltrombopag)"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 08/15/2023","start_date":" 08/15/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-10-18"},{"id":"9006413d-c253-422b-9187-4e378c02068c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05561751","created_at":"2025-03-03T14:53:33.824Z","updated_at":"2025-03-03T14:53:33.824Z","phase":"Phase 2","brief_title":"Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","source_id_and_acronym":"NCT05561751","lead_sponsor":"GPCR Therapeutics, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e burixafor (GPC-100)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/13/2023","start_date":" 02/13/2023","primary_txt":" Primary completion: 03/29/2025","primary_completion_date":" 03/29/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-10-17"},{"id":"0ab65d95-a746-4376-a36a-807e4d1f1ece","acronym":"HBO-UBC","url":"https://clinicaltrials.gov/study/NCT03739502","created_at":"2021-01-18T18:18:53.880Z","updated_at":"2025-02-25T14:15:15.599Z","phase":"Phase 2","brief_title":"A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant","source_id_and_acronym":"NCT03739502 - HBO-UBC","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-08-19"},{"id":"aad15df4-1ae3-483a-b0fd-2eaad8e9fe6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06520176","created_at":"2025-02-27T07:53:36.469Z","updated_at":"2025-02-27T07:53:36.469Z","phase":"Phase 3","brief_title":"Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","source_id_and_acronym":"NCT06520176","lead_sponsor":"The Affiliated People's Hospital of Ningbo University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-25"},{"id":"ee828508-f89b-44a7-a9da-155aa80b2469","acronym":"","url":"https://clinicaltrials.gov/study/NCT06520163","created_at":"2025-02-27T07:53:35.947Z","updated_at":"2025-02-27T07:53:35.947Z","phase":"Phase 3","brief_title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","source_id_and_acronym":"NCT06520163","lead_sponsor":"The Affiliated People's Hospital of Ningbo University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-25"},{"id":"62911df7-cdd6-497a-b828-0b10ea364db9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06514508","created_at":"2025-02-27T07:51:39.520Z","updated_at":"2025-02-27T07:51:39.520Z","phase":"Phase 3","brief_title":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","source_id_and_acronym":"NCT06514508","lead_sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aphexda (motixafortide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-07-23"},{"id":"7a2918a3-5cca-4af4-9ede-643ba7496c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01745588","created_at":"2021-01-18T07:39:01.782Z","updated_at":"2025-02-25T14:33:53.694Z","phase":"Phase 2","brief_title":"Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT01745588","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-03"},{"id":"6c8187f2-a1a7-4e0d-9839-99324cab5154","acronym":"","url":"https://clinicaltrials.gov/study/NCT06022939","created_at":"2023-09-05T18:12:25.015Z","updated_at":"2024-07-02T16:34:27.373Z","phase":"Phase 3","brief_title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","source_id_and_acronym":"NCT06022939","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CD34","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 338","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 07/29/2030","primary_completion_date":" 07/29/2030","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2024-06-11"},{"id":"68d8ce34-194a-45f2-9e93-7c94e62c1815","acronym":"","url":"https://clinicaltrials.gov/study/NCT02356159","created_at":"2021-01-18T11:12:44.041Z","updated_at":"2024-07-02T16:34:36.807Z","phase":"Phase 1/2","brief_title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT02356159","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • ABL1 • BCR • ASXL1 • CD34 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr t(9;11)","tags":["FLT3 • ABL1 • BCR • ASXL1 • CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • sirolimus • fludarabine IV • Kepivance (palifermin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/24/2015","start_date":" 09/24/2015","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-10"},{"id":"8c64ed6b-f5aa-4d8b-8883-487500c8bd4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01370330","created_at":"2021-01-18T05:36:49.021Z","updated_at":"2024-07-02T16:34:59.602Z","phase":"","brief_title":"131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol","source_id_and_acronym":"NCT01370330","lead_sponsor":"Kieuhoa Vo","biomarkers":" IL6 • CD34","pipe":"","alterations":" ","tags":["IL6 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Azedra (iobenguane I 131)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-06-03"}]